Bench-to-bedside review: Vaccine protection strategies during pandemic flu outbreaks

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Chua, Joel V ^a   Chen, Wilbur H ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; PLASMID DNA; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

BACTERIUM CONTAMINATION; CELL CULTURE; DNA TRANSFECTION; DRUG CONTAMINATION; EGG; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MASS IMMUNIZATION; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VIRUS LIKE AGENT; VIRUS STRAIN; DRUG EFFECT; EPIDEMIC; INFLUENZA;

DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 78149247342     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8891     Document Type: Review

References (69)

1. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-42.
2. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bull Hist Med 2002, 76:105-115.
3. Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med 1991, 65:4-21.
4. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000, 18:1436-1447.
5. WHO GAR, Global Alert and Response Summary of Available Potency Testing Reagents for Pandemic (H1N1) 2009 Virus Vaccines - Update 2009, Geneva: WHO, WHO GAR, Global Alert and Response., http://www.who.int/csr/resources/publications/swineflu/cp111b_2009_2011_summary_srid_reagents_H1N1_update.pdf
6. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008, 2:193-202. 2710797, 19453395.
7. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
8. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005, 23:1540-1548.
9. Maassab HF. Plaque formation of influenza virus at 25°C. Nature 1968, 219:645-646.
10. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
11. Alexandrova GI, Maassab HF, Kendal AP, Medvedeva TE, Egorov AY, Klimov AI, Cox NJ. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine 1990, 8:61-64.
12. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of coldadapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R. Antiviral Res 1982, 1:339-365.
13. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008, 26:D41-D44.
14. deJong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
15. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979, 140:844-850.
16. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000, 18:3214-3222.
17. Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16:1009-1015.
18. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2:778-786. 375691, 5701819.
19. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63:1239-1246. 247820, 2915381.
20. Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985, 161:198-209. 2187541, 2981953.
21. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004, 57:236-247.
22. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics - implications for policy. N Engl J Med 2009, 360:2595-2598.
23. Baylor NW, Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr Top Microbiol Immunol 2009, 333:453-470.
24. The Division of Vaccine and Related Product Applications, Center for Biologics Evaluation and Research, FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines 2007, Rockville, MD: US Food and Drug Administration, The Division of Vaccine and Related Product Applications, Center for Biologics Evaluation and Research, FDA., http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf
25. Stephenson I, Gust I, Kieny MP, Pervikov Y. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006, 6:71-72.
26. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005, 26:4-29.
27. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, Clain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363:1099-1103.
28. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110:105-123.
29. Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, Corcoran AT, Iskander JK, Schonberger LB, Chen RT. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis 2008, 198:226-233.
30. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barré syndrome small star, filled. Clin Immunol 2003, 107:116-121.
31. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
32. Evans D, Cauchemez S, Hayden FG. 'Prepandemic' immunization for novel influenza viruses, 'swine flu' vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis 2009, 200:321-328. 2811391, 19563262.
33. Eisen DP, McBryde ES. Avoiding Guillan-Barré syndrome following swine origin pandemic H1N1 2009 influenza vaccination. J Infect Dis 2009, 200:1627-1628.
34. Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs 2008, 68:1483-1491.
35. Gaush CR, Smith TF. Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol 1968, 16:588-594. 547475, 5647517.
36. Meguro H, Bryant JD, Torrence AE, Wright PF. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979, 9:175-179. 272985, 219021.
37. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009, 200:841-848.
38. Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 1998, 16:1331-1335.
39. Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, Treanor J, Gauthier R, Mills EL. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002, 20:1240-1247.
40. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(Suppl 1):S20-S23.
41. Merten OW. Development of serum-free media for cell growth and production of viruses/viral vaccines - safety issues of animal products used in serum-free media. Dev Biol (Basel) 2002, 111:233-257.
42. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
43. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
44. Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, He F, Noah DL, Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008, 198:1309-1316.
45. Global Advisory Committee on Vaccine Safety, World Health Organization Statement from WHO Global Advisory Committee on Vaccine Safety about the Safety Profile of Pandemic Influenza A (H1N1) 2009 Vaccines 2009, Geneva: WHO, Global Advisory Committee on Vaccine Safety, World Health Organization., http://www.who.int/csr/resources/publications/swineflu/cp164_2009_1612_gacvs_h1n1_vaccine_safety.pdf
46. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di GP, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4:e4384. 2634740, 19197383.
47. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
48. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008, 198:642-649.
49. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 1998, 15:1-12.
50. Geeraedts F, Bungener L, Pool J, Ter VW, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses 2008, 2:41-51.
51. Ortbals DW, Liebhaber H. Comparison of immunogenicity of a whole virion and a subunit influenza vaccine in adults. J Clin Microbiol 1978, 8:431-434. 275266, 721947.
52. Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
53. Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe RB, Powers DC. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996, 173:1467-1470.
54. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006, 193:1223-1228.
55. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
56. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8:435-445.
57. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005, 18:244-251.
58. Moss RB. Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Immune Based Ther Vaccines 2009, 7:3. 2746192, 19735569.
59. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008, 197:1643-1652.
60. Schotsaert M, De FM, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8:499-508. 2706389, 19348565.
61. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
62. Novel influenza A(H1N1)v investigation team Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April-16 June 2009. Euro Surveill 2009, 14(31):pii=19295. Novel influenza A(H1N1)v investigation team.
63. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
64. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 2009, 6(14):pii:19288.
65. Vaillant L, La RG, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009, 14(33):pii=19309.
66. Manzoli L, Salanti G, De VC, Boccia A, Ioannidis JP, Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis 2009, 9:482-492.
67. Beigel JH, Voell J, Huang CY, Burbelo PD, Lane HC. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 2009, 200:501-509.
68. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009, 58:1100-1101.
69. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.